GR-46611 (1 mg/kg, i.p. ) significantly improves survival of Dravet syndrome (DS) mice[1].
GR-46611 (0.03-300 μg/kg, i.v.) increases threshold volume, bladder capacity, and residual volume in chronic spinal cord injury (SCI) cats[3].
GR46611 (3-30 mg/kg, s.c.) causes a dose-related decrease in rectal temperature in the adult guinea-pig[4].
| Animal Model: | Dravet syndrome (DS) mice[1] |
| Dosage: | 0.01, 0.1 and 1 mg/kg |
| Administration: | Intraperitoneal injection (i.p.) |
| Result: | Improved survival relative to vehicle treated controls with 89% surviving rate. |
![3-[3-(2-DIMETHYLAMINOETHYL)-1H-INDOL-5-YL]-N-(4-METHOXYBENZYL)ACRYLAMIDE Structure](https://www.chemicalbook.com/CAS/GIF/185259-85-2.gif)
